

# Imre MÃ¶ger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8254883/publications.pdf>

Version: 2024-02-01

49  
papers

10,608  
citations

145106

33  
h-index

214428

50  
g-index

55  
all docs

55  
docs citations

55  
times ranked

17339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Engineered extracellular vesicle decoy receptor-mediated modulation of the IL6 trans-signalling pathway in muscle. <i>Biomaterials</i> , 2021, 266, 120435.	5.7	26
2	Profiling of Extracellular Small RNAs Highlights a Strong Bias towards Non-Vesicular Secretion. <i>Cells</i> , 2021, 10, 1543.	1.8	11
3	Endothelial-Derived Extracellular Vesicles Induce Cerebrovascular Dysfunction in Inflammation. <i>Pharmaceutics</i> , 2021, 13, 1525.	2.0	15
4	Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles. <i>Nature Biomedical Engineering</i> , 2021, 5, 1084-1098.	11.6	41
5	GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain. <i>Nature Communications</i> , 2021, 12, 6666.	5.8	42
6	Extracellular vesicles in neurodegenerative disorders. , 2020, , 285-305.		6
7	An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress. <i>Neurobiology of Disease</i> , 2020, 144, 105050.	2.1	30
8	Efficient Doxorubicin Loading to Isolated Dexosomes of Immature JAWSII Cells: Formulated and Characterized as the Bionanomaterial. <i>Materials</i> , 2020, 13, 3344.	1.3	6
9	CSF extracellular vesicle proteomics demonstrates altered protein homeostasis in amyotrophic lateral sclerosis. <i>Clinical Proteomics</i> , 2020, 17, 31.	1.1	27
10	MiR-219a-5p Enriched Extracellular Vesicles Induce OPC Differentiation and EAE Improvement More Efficiently Than Liposomes and Polymeric Nanoparticles. <i>Pharmaceutics</i> , 2020, 12, 186.	2.0	59
11	A CRISPR-Cas9-based reporter system for single-cell detection of extracellular vesicle-mediated functional transfer of RNA. <i>Nature Communications</i> , 2020, 11, 1113.	5.8	99
12	Extracellular microRNAs exhibit sequence-dependent stability and cellular release kinetics. <i>RNA Biology</i> , 2019, 16, 696-706.	1.5	51
13	UFLCâ€Derived CSF Extracellular Vesicle Origin and Proteome. <i>Proteomics</i> , 2018, 18, e1800257.	1.3	36
14	Therapeutic Potential of Extracellular Vesicles for Demyelinating Diseases; Challenges and Opportunities. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 434.	1.4	33
15	Extracellular Vesicle Heterogeneity: Subpopulations, Isolation Techniques, and Diverse Functions in Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 738.	2.2	638
16	Heterogeneity and interplay of the extracellular vesicle small RNA transcriptome and proteome. <i>Scientific Reports</i> , 2018, 8, 10813.	1.6	118
17	Obstacles and opportunities in the functional analysis of extracellular vesicle RNA â€“ an ISEV position paper. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1286095.	5.5	561
18	Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles. <i>Molecular Therapy</i> , 2017, 25, 1580-1587.	3.7	145

#	ARTICLE	IF	CITATIONS
19	Methodological Guidelines to Study Extracellular Vesicles. <i>Circulation Research</i> , 2017, 120, 1632-1648.	2.0	728
20	C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Brain</i> , 2017, 140, 887-897.	3.7	126
21	Preparation and Isolation of siRNA-Loaded Extracellular Vesicles. <i>Methods in Molecular Biology</i> , 2017, 1545, 197-204.	0.4	6
22	Reproducible and scalable purification of extracellular vesicles using combined bind-elute and size exclusion chromatography. <i>Scientific Reports</i> , 2017, 7, 11561.	1.6	168
23	Targeting blood-brain-barrier transcytosis – perspectives for drug delivery. <i>Neuropharmacology</i> , 2017, 120, 4-7.	2.0	74
24	Proteostasis and Diseases of the Motor Unit. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 164.	1.4	4
25	Extracellular vesicles in neurodegenerative disease – pathogenesis to biomarkers. <i>Nature Reviews Neurology</i> , 2016, 12, 346-357.	4.9	299
26	Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation. <i>Human Molecular Genetics</i> , 2016, 25, 3960-3974.	1.4	50
27	Cells release subpopulations of exosomes with distinct molecular and biological properties. <i>Scientific Reports</i> , 2016, 6, 22519.	1.6	728
28	Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 26316.	5.5	1,077
29	Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods. <i>PLoS ONE</i> , 2015, 10, e0145686.	1.1	493
30	Extracellular microRNAs in Membrane Vesicles and Non-vesicular Carriers. <i>Exs</i> , 2015, 106, 31-53.	1.4	7
31	Therapeutic Potential of Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles. <i>Human Gene Therapy</i> , 2015, 26, 506-517.	1.4	148
32	Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 879-883.	1.7	487
33	Serum-free culture alters the quantity and protein composition of neuroblastoma-derived extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 26883.	5.5	131
34	From Gut to Brain: Bioencapsulated Therapeutic Protein Reduces Amyloid Load Upon Oral Delivery. <i>Molecular Therapy</i> , 2014, 22, 485-486.	3.7	13
35	Sensitive and Rapid Detection of <i>Chlamydia trachomatis</i> by Recombinase Polymerase Amplification Directly from Urine Samples. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 127-135.	1.2	120
36	Exosomes for targeted siRNA delivery across biological barriers. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 391-397.	6.6	430

#	ARTICLE	IF	CITATIONS
37	PepFect14 Peptide Vector for Efficient Gene Delivery in Cell Cultures. <i>Molecular Pharmaceutics</i> , 2013, 10, 199-210.	2.3	83
38	Extracellular vesicles: biology and emerging therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 347-357.	21.5	2,563
39	Use of Cell-Penetrating-Peptides in Oligonucleotide Splice Switching Therapy. <i>Current Gene Therapy</i> , 2012, 12, 161-178.	0.9	23
40	The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2012, 1818, 502-511.	1.4	80
41	Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. <i>Nucleic Acids Research</i> , 2011, 39, 3972-3987.	6.5	262
42	A Peptide-based Vector for Efficient Gene Transfer In Vitro and In Vivo. <i>Molecular Therapy</i> , 2011, 19, 1457-1467.	3.7	94
43	Prediction of Cell-Penetrating Peptides Using Artificial Neural Networks. <i>Current Computer-Aided Drug Design</i> , 2010, 6, 79-89.	0.8	49
44	Delivery of nucleic acids with a stearylated (RxR) <sub>4</sub> peptide using a non-covalent co-incubation strategy. <i>Journal of Controlled Release</i> , 2010, 141, 42-51.	4.8	113
45	Characterization of Bioactive Cell Penetrating Peptides from Human Cytochrome c: Protein Mimicry and the Development of a Novel Apoptogenic Agent. <i>Chemistry and Biology</i> , 2010, 17, 735-744.	6.2	51
46	Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2010, 1798, 338-343.	1.4	64
47	In vivo biodistribution and efficacy of peptide mediated delivery. <i>Trends in Pharmacological Sciences</i> , 2010, 31, 528-535.	4.0	127
48	Cellular Internalization Kinetics of (Luciferin-)Cell-Penetrating Peptide Conjugates. <i>Bioconjugate Chemistry</i> , 2010, 21, 1662-1672.	1.8	42
49	Finger beat-to-beat blood pressure responses to successive hand elevations. <i>Medical Engineering and Physics</i> , 2009, 31, 522-527.	0.8	8